Switching from efavirenz/tenofovir/emtricitabine (TDF/FTC/EFV) to abacavir/lamivudine/maraviroc (ABC/3TC/MVC) to assess antiretroviral activity in cerebrospinal fluid: a prospective one-arm pilot study.
Phase of Trial: Phase IV
Latest Information Update: 29 Jul 2014
At a glance
- Drugs Lamivudine/abacavir (Primary) ; Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms MRVstudy-10 (XUMAKER); XUMAKER
- 02 Apr 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 21 Apr 2011 New trial record